Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma calls off Injectables sale

This article was originally published in Scrip

Executive Summary

Hikma has decided against selling off its global Injectables business, which analysts had valued at up to $2.2 billion (scripintelligence.com, 4 March 2013). The Jordanian headquartered company Hikma had been conducting a strategic review of options following significant interest in the unit apparently sparked Mylan's $1.6 billion acquisition of Strides Arcolab's similar business Agila Specialities earlier this year. Companies such as Pfizer and Novartis were rumored to have been disappointed bidders for Agila (scripintelligence.com, 28 February 2012).

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel